- Home
- LE vs AVIR Comparison
LE vs AVIR Comparison
Compare LE & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LE
- AVIR
- Stock Information
- Founded
- LE 1963
- AVIR 2012
- Country
- LE United States
- AVIR United States
- Employees
- LE N/A
- AVIR N/A
- Industry
- LE Clothing/Shoe/Accessory Stores
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- LE Consumer Discretionary
- AVIR Health Care
- Exchange
- LE Nasdaq
- AVIR Nasdaq
- Market Cap
- LE 274.7M
- AVIR 273.7M
- IPO Year
- LE N/A
- AVIR 2020
- Fundamental
- Price
- LE $8.42
- AVIR $2.97
- Analyst Decision
- LE Strong Buy
- AVIR Hold
- Analyst Count
- LE 1
- AVIR 1
- Target Price
- LE $20.00
- AVIR $6.00
- AVG Volume (30 Days)
- LE 216.7K
- AVIR 441.1K
- Earning Date
- LE 06-05-2025
- AVIR 05-12-2025
- Dividend Yield
- LE N/A
- AVIR N/A
- EPS Growth
- LE N/A
- AVIR N/A
- EPS
- LE 0.20
- AVIR N/A
- Revenue
- LE $1,362,935,000.00
- AVIR N/A
- Revenue This Year
- LE $4.26
- AVIR N/A
- Revenue Next Year
- LE $2.67
- AVIR N/A
- P/E Ratio
- LE $42.16
- AVIR N/A
- Revenue Growth
- LE N/A
- AVIR N/A
- 52 Week Low
- LE $7.65
- AVIR $2.46
- 52 Week High
- LE $19.88
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- LE 43.03
- AVIR 56.05
- Support Level
- LE $8.52
- AVIR $2.78
- Resistance Level
- LE $9.15
- AVIR $3.03
- Average True Range (ATR)
- LE 0.39
- AVIR 0.17
- MACD
- LE 0.01
- AVIR 0.03
- Stochastic Oscillator
- LE 0.85
- AVIR 88.03
About LE Lands' End Inc.
Lands' End Inc is a United States-based multi-channel retailer of casual clothing, accessories, and footwear, as well as home products. The company's operating segment includes U.S. eCommerce; International; Outfitters; Third Party and Retail. It generates maximum revenue from the U.S. eCommerce segment. The U.S. eCommerce segment offers products through the company's eCommerce website. Geographically, it derives a majority of its revenue from the United States.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).